speakerspeaker

mRNA therapeutics is a rapidly expanding industry

mRNA therapeutics market expected to reach USD 25 billion by 2030

Read more here

Personalised Treatments with mRNA

Breakthrough research that shows a promising future for personalised cancer therapy

Secure your place

Development of mRNA Technology

The best technologies and what works most effectively to help with manufacturing and other stages of mRNA development

View the latest program

Expert Speakers to Date

  • Jeff Gilmore
    cGMPnow
  • Andrew Mancini
    Marken
  • Elisa Cuevas
    4basebio
  • Divita Gilles
    DIVINCELL
  • Jessica Kenison
    Mass General Brigham
  • Amy Rappaport
    Gritstone bio
  • Daniel Griffith Anderson
    Massachusetts Institute of Technology 
  • Suresh Peddigari
    Moderna
  • Stuart Milstein
    Senda Biosciences
  • Gilles Besin
    Orbital Therapeutics

Past Attendees

  • GenVault 
  • Macherey-Nagel
  • Orna Therapeutics
  • Beckman Coulter Life Sciences
  • University of Pennsylvania
  • ProtaGene
  • CSL Seqirus
  • University of Washington (Seattle)
  • Shanghai Jiao Tong University, School of Medicine
  • Catalent Pharma Solutions
  • cGMPnow
  • EMD Serono
  • Emergent Bioservices
  • MINISTRY OF HEALTH, MALAYSIA
  • HealthMatch

Who should attend

  • mRNA Therapeutics
  • Immunotherapeutics
  • Blockchain Technology
  • mRNA Technologies
  • Genetic Engineering
  • DNA, mRNA Technologies
  • Viral Vector-Based Vaccines
  • Nucleic Acid-Based Vaccines
  • Vaccine Delivery Platforms
  • Biological Engineering of Vaccines
  • Structural Vaccinology Projects
  • Advanced Live-Attenuated Vaccines
  • Inactivated Vaccine Development
  • Cost Reduction Strategies
  • Sales and Marketing Initiatives
  • Business Development
  • Clinical Trials and Approvals
  • Immunisation Research & Development
  • Manufacturing Research & Innovation
  • Research and Development
  • Strategy, Projects, & Public Affairs
  • Legal and Compliance Work
  • Equipment Certification Services
  • News Reporting and Journalism
  • Biotechnology Companies
  • Pharmaceutical Companies
  • Vaccination Developers
  • Vaccine Researchers
  • Vaccine Technology Companies
  • Immunisation Specialists
  • Public Healthcare Providers
  • Genetic Engineering Companies
  • Global Healthcare Institutions
  • Clinical Research Organisations
  • Vaccine Delivery Technologies
  • Vaccines Manufacturing
  • Vaccinology Research & Development
  • Biological Engineering Companies
  • DNA and Messenger RNA Researchers
  • International Quality Standards
  • Associations and Alliances
  • Universities and Academia
  • Research and Development
  • Government Agencies
  • Consultants and Advisors
  • Public Consultation Groups
  • Legal and Compliance Services
  • News Reporters and Journalists

Why Attend

The mRNA Conference is the only event to deliver leading market intelligence and industry presentations on the latest in next-generation mRNA therapeutics, formulations, and clinical development.…

view more...

Subscribe for updates:

The Premier Forum for mRNA-Based Therapeutics and Drug Development

Welcome to The mRNA Conference 2024, where global pharmaceutical and biotech companies will meet with world-leading industry experts in Frankfurt, Germany, to explore the latest innovations in mRNA-based therapeutics and vaccines for infectious diseases, oncology, CAR-T cell therapies, and beyond.

Recent vaccine success has put mRNA technology into the spotlight with increasingly growing potential for applications in immunotherapy, personalised medicine, and clinical treatments of genetic, infectious, and chronic diseases. The mRNA conference will focus on developing mRNA vaccines and therapies from early research to commercialisation and clinical applications.

This exclusive event will showcase invaluable insights into differentiated drug platforms through RNA modification and delivery systems, next-generation mRNA therapeutics, formulations, clinical development, and supply chain and logistics.

Key topics on this year’s agenda include:

  • The future of mRNA-based therapeutics for infectious disease and beyond
  • Latest advancements in mRNA formulation and delivery technologies
  • Breakthrough research in personalised mRNA treatments and immunotherapy
  • Blockchain technology for mRNA-based therapeutics supply chain solutions
  • Challenges and bottlenecks in the global manufacturing of mRNA vaccines
  • Regulatory and healthcare considerations in mRNA-based clinical development

The mRNA Conference 2024 is set to become the world’s leading event exclusively for the biotech and pharma industry to meet and collaborate with RNA technology experts, examine new technologies and technical know-how, and discuss the opportunities associated with next-generation mRNA therapeutics, formulations, and clinical development.

Call for Presentation

If you would like to be a speaker at this event, please contact sean.collins@iQ-Hub.com, subject heading “Call for Papers - The mRNA Conference 2024”.

Book now
To secure your place at The mRNA Conference 2024 or if you require more information, please contact delegates@iQ-Hub.com.

SPONSORS / EXHIBITORS

Key topics for 2024:

  • The future of mRNA-based therapeutics for infectious disease and beyond
    Hear about innovations, the limitless future of mRNA therapeutics, and a new class of drugs.
  • Latest advancements in mRNA formulation and delivery technologies
    Learn about delivering the messenger and technological advancements for therapeutic mRNA delivery from concept to clinical reality.
  • Breakthrough research in personalised mRNA treatments and immunotherapy
    Understand the most recent technological advances towards personalised, tumor-specific, mRNA therapeutic vaccines for cancer.
  • Blockchain technology for mRNA-based therapeutics supply chain solutions
    Gain insight into the blockchain-enabled pharmaceutical cold chain and supply chain transparency through blockchain-based traceability.
  • Challenges and bottlenecks in the global manufacturing of mRNA vaccines
    Explore the latest innovative and rapid development and deployment of high‐volume vaccines for pandemic responses.
  • Regulatory and healthcare considerations in mRNA-based clinical development
    Learn the key regulatory and commercial concerns to approve and accept mRNA-based therapeutics to treat diseases.

Testimonials

  • Highly informational event with lots of opportunities to engage with other people from the field.
    Ying Wang, Johnson & Johnson
  • Excellent speaker line up. Showcasing the science and results from across the industry.
    Anne Renton, Merck
  • Well organized and great discussions. Networking opportunities were excellent.
    Carolyn Dulney, Roche
  • Provided a great learning opportunity and served as a very good networking event.
    Mike Zimmer, Novartis
  • I loved the show! Very informative conference and a great group of people.
    Wensheng Du, GlaxoSmithKline
  • Excellent conference. Very useful information. Well organized event and agenda was very appropriate.
    Barry Rosen, Sanofi
Back to Top
MEET THE LEADERS: